Zoetis Inc. (NYSE:ZTS) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 46.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,188 shares of the company's stock after purchasing an additional 28,129 shares during the quarter. Quantinno Capital Management LP's holdings in Zoetis were worth $14,531,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis in the fourth quarter worth $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis in the fourth quarter worth about $44,000. Finally, Asset Planning Inc purchased a new stake in shares of Zoetis in the fourth quarter worth about $58,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Stifel Nicolaus decreased their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Finally, Piper Sandler raised their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $212.75.

Zoetis Stock Performance

Shares of ZTS stock traded up $2.68 on Friday, hitting $163.03. 2,391,686 shares of the stock traded hands, compared to its average volume of 2,513,944. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company's fifty day moving average is $156.46 and its 200 day moving average is $165.43. The company has a market capitalization of $72.58 billion, a PE ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.